Skip to main content
Premium Trial:

Request an Annual Quote

Genencor and University of Leicester Seek New Genes in Inner Mongolia

NEW YORK, Oct. 8-The European Union is funding a three-year collaborative study with the People's Republic of China to identify new microbes, enzymes and genes from remote locations in inner Mongolia and Tibet.

 

The European Commission is providing EURO1 million for the project, which involves collaborators from the California firm Genencor, the University of Leicester, the Chinese Academy of Sciences in Beijing, the University of Seville in Spain and the University of the Western Cape in South Africa.

 

Researchers from this consortium will use on-site DNA extraction to identify new genes from these isolated environments. Genencor will provide high-throughput robotic screening, microarray and bioinformatics expertise. The company will focus on identifying previously unknown enzymes from extreme environments that may be developed for commercial use.

 

For more information, see the press release.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.